JP2022512043A5 - - Google Patents

Info

Publication number
JP2022512043A5
JP2022512043A5 JP2021547634A JP2021547634A JP2022512043A5 JP 2022512043 A5 JP2022512043 A5 JP 2022512043A5 JP 2021547634 A JP2021547634 A JP 2021547634A JP 2021547634 A JP2021547634 A JP 2021547634A JP 2022512043 A5 JP2022512043 A5 JP 2022512043A5
Authority
JP
Japan
Prior art keywords
fusion protein
protein according
cancer
identification number
sequence identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547634A
Other languages
English (en)
Japanese (ja)
Other versions
JP7496091B2 (ja
JP2022512043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/114026 external-priority patent/WO2020088459A1/en
Publication of JP2022512043A publication Critical patent/JP2022512043A/ja
Publication of JP2022512043A5 publication Critical patent/JP2022512043A5/ja
Application granted granted Critical
Publication of JP7496091B2 publication Critical patent/JP7496091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547634A 2018-10-29 2019-10-29 合理的に設計された新規なタンパク質組成物 Active JP7496091B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752293P 2018-10-29 2018-10-29
US62/752,293 2018-10-29
US201962811116P 2019-02-27 2019-02-27
US62/811,116 2019-02-27
PCT/CN2019/114026 WO2020088459A1 (en) 2018-10-29 2019-10-29 Novel rationally designed protein compositions

Publications (3)

Publication Number Publication Date
JP2022512043A JP2022512043A (ja) 2022-02-01
JP2022512043A5 true JP2022512043A5 (cg-RX-API-DMAC7.html) 2022-10-26
JP7496091B2 JP7496091B2 (ja) 2024-06-06

Family

ID=70462528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547634A Active JP7496091B2 (ja) 2018-10-29 2019-10-29 合理的に設計された新規なタンパク質組成物

Country Status (12)

Country Link
US (1) US12378295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873945A4 (cg-RX-API-DMAC7.html)
JP (1) JP7496091B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210087965A (cg-RX-API-DMAC7.html)
CN (1) CN113166272B (cg-RX-API-DMAC7.html)
AU (1) AU2019371994A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008204A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117853A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004916A (cg-RX-API-DMAC7.html)
SG (1) SG11202104297XA (cg-RX-API-DMAC7.html)
TW (1) TWI840433B (cg-RX-API-DMAC7.html)
WO (1) WO2020088459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020038379A1 (en) * 2018-08-20 2020-02-27 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CN115916831A (zh) * 2020-06-30 2023-04-04 Gi 医诺微新 包含抗lag-3抗体和il-2的融合蛋白及其用途
JP7819944B2 (ja) * 2020-07-09 2026-02-25 ユーティレックス カンパニー リミテッド Il-2バリアント
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN120518765A (zh) * 2025-02-08 2025-08-22 龙启生物科技(上海)有限公司 一种结合人CD8β的VHH及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CN107915777A (zh) * 2016-10-09 2018-04-17 泰州迈博太科药业有限公司 一种重组免疫细胞因子及其应用
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) * 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체

Similar Documents

Publication Publication Date Title
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
US10047163B2 (en) Multispecific constructs
US7262276B2 (en) Anti human ovarian cancer-anti CD3 bispecific antibody
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7549961B2 (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
CA3117853A1 (en) Novel rationally designed protein compositions
WO2014180577A1 (en) Bispecific constructs and their use in the treatment of various diseases
JP2021512151A5 (cg-RX-API-DMAC7.html)
JP2020530770A5 (cg-RX-API-DMAC7.html)
WO2019196309A1 (zh) 抗pd-l1抗体及其用途
JP2022512891A5 (cg-RX-API-DMAC7.html)
KR20240046224A (ko) 이중특이성 항체 및 그 용도
JP2026514663A (ja) Tnfスーパーファミリーメンバー免疫サイトカイン及びその使用
JP2021534750A5 (cg-RX-API-DMAC7.html)
KR20240127523A (ko) 항-cntn4 항체 및 그의 용도
RU2021112298A (ru) Полученные путем рационального дизайна новые белковые композиции
CN116874606B (zh) 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
JP2023523760A5 (cg-RX-API-DMAC7.html)
CN120958019A (zh) 针对人分化簇3蛋白的抗体及其变体
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof
HK40054346A (en) Protease cleavable bispecific antibodies and uses thereof
HK40054346B (en) Protease cleavable bispecific antibodies and uses thereof
HK40018991A (en) Multi-specific antibodies and methods of making and using thereof
HK40022867A (en) Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa